Transfusion and Apheresis Science
Volume 41, Issue 3 , Pages 199-204 , December 2009

The influence of riboflavin photochemistry on plasma coagulation factors

  • Luis Larrea

      Affiliations

    • Centro de Transfusión de la Comunidad Valenciana, Processing Department, Spain
    • Corresponding Author InformationCorresponding author. Address: Avda Del Cid 65, 46014 Valencia, Spain. Tel.: +34 963868143; fax: +34 963502469.
    • ,
  • María Calabuig

      Affiliations

    • Centro de Transfusión de la Comunidad Valenciana, Processing Department, Spain
    • ,
  • Vanesa Roldán

      Affiliations

    • Centro Regional de Hemodonacion, Unit of Hematology–Oncology, Spain
    • ,
  • José Rivera

      Affiliations

    • Centro Regional de Hemodonacion, Unit of Hematology–Oncology, Spain
    • ,
  • Han-Mou Tsai

      Affiliations

    • Montefiore Medical Center/Albert Einstein Collage of Medicine, Division of Hematology, Spain
    • ,
  • Vicente Vicente

      Affiliations

    • Centro Regional de Hemodonacion, Unit of Hematology–Oncology, Spain
    • ,
  • Roberto Roig

      Affiliations

    • Centro de Transfusión de la Comunidad Valenciana, Processing Department, Spain

References 

  1. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci. 2006;35:83–90
  2. Bryant BJ, Klein HG. Pathogen inactivation. The definitive safeguard for the blood supply. Arch Pathol Lab Med. 2007;13:719–733
  3. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma what is its contribution to blood safety?. Transfusion. 2003;43:1322–1329
  4. Sandler SG. The case for pathogen inactivation of blood components. Curr Opin Hematol. 2005;12:471–472
  5. Allain JP, Bianco C, Blachman MA, Brecher ME, Busch M, Leiby D, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev. 2005;19:110–126
  6. Pelletier JPR, Transue S, Zinder EL. Pathogen inactivation techniques. Best Pract Research Clin Haematol. 2006;19:205–242
  7. Ruane P, Edrich R, Gampp D, Keil S, Leonard L, Goodrich R. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877–885
  8. Goodrich RP, Li J, Edrich R, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci. 2006;35:5–17
  9. Goodrich RP, Edrich RA. The antiviral and antibacterial properties of riboflavin and light: applications to blood safety and transfusion medicine. In: Silva E, Edwards AM, editors. Comprehensive series in photochemistry and photobiology, vol. 6, flavins: photochemistry and photobiology, Cambridge, UK: Royal Society of Chemistry; 2006.
  10. Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich RP. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrations using riboflavin and light. Vox Sang. 2007;37:131–137
  11. Cardo L, Rentas F, Ketchum L, Salata J, Harman R, Melvin W, et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and light. Vox Sang. 2006;90:85–91
  12. Fast LD, Dileone G, Li J, Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion. 2006;46:642–648
  13. Tsai H, Chandler W, Sarode R, Hoffman R, Jelacic S, Habeeb RL, et al. Von Willebrand factor and Von Willebrand factor – cleaving metalloprotease activity in Escherichia coli 0157: H7 – associated hemolytic uremic syndrome. Pediatr Res. 2001;49:5
  14. European Committee on Blood Transfusion. Guide to the preparation, use and quality assurance of blood components. 14th ed.; 2008.
  15. Hellstern P, Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res. 2002;107(Suppl. 1):S3–S8
  16. Rosen S, Cason MC. Determination of factor VIII activity in plasma and concentrates: comparison between methods. Am Clin Lab. 2002;32–37
  17. Buytaert-Hoefen K, Gampp D, Edrich R, Hendrix B, Goodrich R. Mirasol pathogen treated frozen plasma maintains protein quality. Transfusion. 2007;47(3S):SP88
  18. Beeck H, Hellstern P. In vitro characterization of solvent/detergent treated human plasma and of quarantine fresh frozen plasma. Vox Sang. 1998;74(Suppl. 1):219–223
  19. Hellstern P, Sachse H, Schwinn H, Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang. 1992;63:178–185
  20. Lutze G, Hartung KJ. Gerinnungsfaktoren-Aktivitäts-und Konzentrationsbestimmungen in konventionellen und virusinaktivierten gerinnungsaktiven Plasmen. Krankenhauspharmazie. 1994;15:517–522
  21. Leebeek FWG, Schipperus MR, van Vliet HHDM. Coagulation factor levels in solvent/detergent-treated plasma. Transfusion. 1999;39:1150–1151
  22. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med. 2004;14:39–44
  23. Garwood M, Cardigan RA, Drummond O, Hornsey VS, Turner CP, Young D, et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion. 2003;43:1238–1247
  24. Schlenke P, Hervig T, Isola H, Wiesel ML, Kientz D, Pinkoski L, et al. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion. 2008;48:697–705
  25. Allford SL, Harrison P, Lawrie AS, MacKie IJ, Machin SJ. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol. 2000;111:1215–1222
  26. Kiss JE. Randomized clinical trials in thrombotic thrombocytopenic purpura: where do we go from here?. Transfusion. 2006;46:1659–1662
  27. Adcock DM, Bethel M, Valcour A. Diagnosing von Willebrand disease: a large reference laboratory’s perspective. Semin Thromb Hemost. 2006;32:472–479

PII: S1473-0502(09)00143-8

doi: 10.1016/j.transci.2009.09.006

Transfusion and Apheresis Science
Volume 41, Issue 3 , Pages 199-204 , December 2009

Article Tools